Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Oct 02, 2026
RKLX ETF: +21% Rebound Over 30 Days as Rocket Lab Shares Recover

RKLX ETF: +21% Rebound Over 30 Days as Rocket Lab Shares Recover

Key Takeaways

  • RKLX advanced roughly 21% over the trailing 30 days, rebounding from multi-month lows while remaining far below its 52-week high.
  • The fund seeks 2x (200%) of the daily percentage change in RKLB (Rocket Lab USA) shares, making it a short-term trading vehicle rather than a buy-and-hold position.
  • The move largely mirrors a rebound in Rocket Lab, whose shares rose about 13% over the same period.
  • Over the last quarter, RKLX fell approximately 60%, reflecting a decline in Rocket Lab combined with the compounding effects of daily 2x leverage.
  • Because the fund rebalances daily, multi-day returns can diverge materially from a simple 2x multiple of the underlying stock.

Understanding the RKLX ETF and Its Exposure to Rocket Lab

The Defiance Daily Target 2X Long RKLB ETF (RKLX) is an actively managed, single-stock leveraged ETF listed on Nasdaq. It seeks daily investment results, before fees and expenses, equal to 200% of the daily percentage change in the share price of Rocket Lab USA, Inc. (RKLB), a space launch and space systems company known for its Electron small-lift rocket and the Neutron medium-lift vehicle in development.

The fund obtains leveraged exposure primarily through swap agreements and listed options rather than direct ownership of Rocket Lab shares. Its portfolio holds a small number of positions, largely collateral such as cash and Treasury instruments that back the derivatives exposure. The ETF is classified as non-diversified, carries a gross expense ratio of 1.29%, and holds roughly $190 million in assets under management. It began trading in March 2025.

This structure means RKLX is effectively a concentrated, leveraged bet on a single aerospace and defense company. Its entire price trajectory—both the recent rebound and the prior drawdown—is a function of Rocket Lab's share price, amplified by daily 2x leverage and subject to the path-dependent effects of daily compounding. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the aerospace sector.

RKLX Performance: 30-Day Gains Versus Quarterly Losses

Over the trailing 30 days, RKLX climbed approximately 21%, moving from a closing price near $14.38 to roughly $17.44. The advance was not a smooth uptrend; the fund traded in a wide band, dipping near its 52-week low territory before staging a sharp recovery in the latter part of the period.

The broader quarter tells a different story. Over the prior three months, RKLX declined about 60%, falling from a closing level near $43 in early July to the $17 area. That decline was trend-driven and highly volatile, with the fund's 52-week range spanning from roughly $13.29 to $114.83. In other words, the recent 30-day gain represents a partial recovery from a deep leveraged selloff rather than a new sustained uptrend.

Drivers Behind the Recent 30-Day Move

The primary driver of RKLX over the last 30 days was a rebound in Rocket Lab shares, which advanced roughly 13% from the low-$60 range to about $70. Because RKLX targets twice the daily move of Rocket Lab, positive days in the underlying stock produced outsized gains in the ETF.

Rocket Lab operates in the space launch and space systems market, a sector that has drawn investor attention from rising commercial launch demand and growing government and defense space budgets. Sentiment toward high-growth space and aerospace names improved during the period, supporting the underlying stock and, in turn, the leveraged fund. From what I see, this sector momentum is worth tracking closely.

Notably, the leveraged structure did not deliver a full 2x multiple of the underlying's move over the full 30-day window. Rocket Lab's 13% rise, compounded at 2x daily leverage, would imply a gain above 25%; RKLX's actual gain of about 21% reflects volatility drag—the mathematical cost of daily rebalancing during a choppy period. This divergence is a defining feature of leveraged ETFs and underscores why they are designed for short holding periods.

Factors Behind the Quarterly Decline

Over the last quarter, RKLX fell roughly 60% as Rocket Lab shares declined about 30%, from near $100 in early July to about $70. Leverage amplified the underlying weakness, while volatility drag compounded the losses during a period of sharp, multiday swings in the space and growth sectors.

High-growth, capital-intensive names such as Rocket Lab are particularly sensitive to interest-rate expectations and shifts in risk appetite. A period of risk-off rotation away from speculative growth equities weighed on the underlying stock, and the daily 2x mechanism magnified the drawdown in RKLX. The fund's decline from multi-month highs into its 52-week low area illustrates how quickly leveraged single-stock products can move in both directions.

Using Tickeron’s AI Screener in My Research

Tickeron’s AI Screener has become a regular part of how I evaluate leveraged ETFs like RKLX. It lets me scan for momentum, volatility, and sector rotation signals across thousands of securities, which helps put single-stock products in better context. I find it especially useful for spotting how RKLX stacks up against broader aerospace trends without spending hours on manual screens. Explore the AI Screener if you want to streamline similar analysis.

RKLX ETF Outlook: What Investors Should Watch Next

The outlook for RKLX is inseparable from Rocket Lab's fundamentals and the broader risk environment. Investors should monitor the company's launch cadence, progress on the Neutron medium-lift rocket, and the growth of its space systems and satellite-manufacturing business, all of which influence the underlying stock.

Macroeconomic conditions remain important. Interest-rate expectations and investor appetite for high-growth, capital-intensive equities will continue to shape Rocket Lab's valuation and, through daily 2x leverage, RKLX's daily swings. Volatility itself is a key risk: over multi-day holding periods, daily rebalancing can erode returns even if the underlying stock ultimately rises.

Finally, capital flows into and out of leveraged single-stock products and shifts in space-sector sentiment can amplify price moves. Prospective holders should treat RKLX as a tactical, short-duration instrument and weigh the structural risks of daily compounding alongside any directional view on Rocket Lab.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RKLX

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for RKLX turns positive, indicating new upward trend

RKLX saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator turned positive. In 21 of the 22 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RKLX's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for RKLX just turned positive on September 08, 2026. Looking at past instances where RKLX's MACD turned positive, the stock continued to rise in 12 of 13 cases over the following month. The odds of a continued upward trend are 90%.

Following a +10.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where RKLX advanced for three days, in 89 of 92 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 16 cases where RKLX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

RKLX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

RKLX broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RKLX entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Rocket Lab USA, Inc. The fund is an actively managed exchange traded fund (“ETF”) that attempts to achieve two times (200%) the daily percentage change in the share price of the underlying security by employing derivatives, namely swap agreements and/or listed options contracts. The fund is non-diversified.
View a ticker or compare two or three
RKLX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
United States
Phone
N/A
Web
N/A
Interact to see
Advertisement
MRSH stock declined approximately -9% over the past 30 days, driven by sector-wide AI disruption fears and analyst downgrades. Over the past quarter, the stock fell around -7%, amid softening insurance rates and declining fiduciary interest income.
MCO stock declined approximately -9% over the last 30 days amid profit-taking, insider selling, and sector-wide concerns in financial data analytics. Over the past quarter, shares fell around -18%, reflecting a correction from January highs despite strong Q4 2025 earnings. Key drivers include post-earnings selloff after Q4 results, analyst price target cuts, and broader market volatility in credit ratings sector.
SNOW stock declined approximately -9% over the last 30 days, from around $168 to $153, amid post-earnings profit-taking and analyst caution despite strong results. Over the past quarter, the stock fell about -31%, from near $223, reflecting broader sector pressures and valuation concerns in cloud software.
WDS stock surged +24% over the past 30 days, driven by a sharp rally in oil and LNG prices amid Middle East supply disruptions, including Strait of Hormuz issues and strikes on Qatar's Ras Laffan facility. Over the past quarter, the stock climbed +55%, reflecting sustained energy market volatility and Woodside's strong production from assets like Sangomar and Pluto LNG.
HMC stock declined -19% over the past 30 days amid major setbacks in EV strategy, including cancellation of North American EV models and up to $15.7 billion in related losses. Over the past quarter, shares fell -18%, driven by persistent auto segment weakness, tariff impacts, and revised FY2026 forecasts to a net loss. Key catalysts include March EV reassessment announcement causing a 5%+ drop, Q3 earnings beat overshadowed by one-time charges and guidance concerns, and Sony-Honda JV EV project halt.
EL stock plunged approximately -39% over the past 30 days amid merger discussions with Puig, tariff pressures, and restructuring costs, marking a highly volatile period. Over the past quarter, the stock is down around -37%, reflecting broader sector headwinds despite earlier quarterly earnings beats. Key drivers include confirmation of potential business combination with Puig sparking uncertainty, ongoing $100 million tariff impacts, and elevated restructuring expenses.
ESLT stock rose +13% over the past 30 days, driven primarily by a blowout Q4 2025 earnings report with revenue up 11% and EPS beating estimates by over 10%. Over the past quarter, shares surged +52%, fueled by a record $28.1 billion order backlog, up significantly year-over-year, amid heightened global defense demand. Geopolitical tensions in the Middle East boosted demand for Elbit's systems, alongside major contract wins totaling hundreds of millions from international clients.
EQT stock rose approximately +10% over the last 30 days, driven by strong Q4 2025 earnings beat, robust free cash flow guidance for 2026, and analyst price target increases. Over the past quarter, shares gained around +23%, fueled by operational efficiencies, natural gas price recovery, and positive sector sentiment amid LNG demand growth.
Robin Energy Ltd is a Cyprus-based shipping company focused on ocean and deep-sea freight transportation. As a holding entity, it acquires, owns, charters, and manages oceangoing tanker vessels worldwide. The core of its business lies in energy transportation services, mainly through handysize tankers and LPG carriers. In the competitive marine shipping industry, RBNE positions itself as a growth-oriented player, expanding its fleet and locking in multi-year charters. Recent developments, such as vessel acquisitions and Bitcoin treasury allocations, leave it exposed to shipping cycles and alternative asset volatility. From what I see, this mix contributes to the erratic stock price behavior we've observed amid shifting global energy demand and freight rates.
NG stock plunged -42% over the past 30 days amid sharp declines from mid-March peaks around $14, driven by profit-taking after a multi-year rally and sector-wide weakness in gold mining stocks. Over the past quarter, the stock is down -14%, reflecting volatility from early-year gains tied to financing successes offset by recent macro pressures and permitting concerns. Key drivers include gold price fluctuations due to interest rate expectations, profit-taking post-240%+ annual surge, and no immediate production revenue despite Donlin Gold project advancements.
CRBU stock declined approximately -10% over the past 30 days, reflecting volatility amid clinical updates and financing concerns. Over the past quarter, the stock rose about +12%, driven by positive earnings beats and pipeline progress. Key drivers include Q4 2025 earnings beat, vispa-cel Phase 3 plans, but offset by cash burn and need for additional capital.
Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63. The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event.
SYY shares are trading approximately -6.40% lower in premarket trading on March 30, 2026, from a prior close of $81.80 to roughly $76.56. The primary catalyst is Sysco's announcement of a $29.1 billion definitive agreement to acquire Jetro Restaurant Depot, one of the nation's largest Cash & Carry food wholesalers.
Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.
FingerMotion, Inc. (FNGR) operates as a mobile data specialist, delivering mobile payment and recharge platform solutions mainly in China. The company's core revolves around telecommunication products and services, such as top-up recharges, data plans, SMS and MMS services, big data insights for consumer behavior analysis, and rich communication services (RCS) platforms. It also provides value-added products through partnerships with telecom providers and e-commerce platforms.
NIO Inc. (NIO) stands out as a leading Chinese electric vehicle manufacturer focused on premium smart EVs. The company designs, develops, and sells high-end battery electric vehicles, bolstered by its Battery-as-a-Service model that lets customers swap batteries at stations rather than owning them. In the cutthroat Chinese EV space, NIO competes directly with firms like XPEV and LI.
Xcel Energy Inc. (XEL) stands out as a major U.S. electric and natural gas utility, serving about 3.7 million electric and 2.2 million natural gas customers across eight states, mainly in the Midwest and West. The company focuses on regulated utilities, handling electricity generation, transmission, and distribution, while increasingly prioritizing renewable sources like wind and solar. Its model centers on steady, regulated returns from infrastructure investments, backed by rate cases and recovery mechanisms.
Occidental Petroleum Corporation (OXY) stands out as a leading independent energy producer, with a primary focus on hydrocarbon exploration and production. The company has significant operations in the Permian Basin, one of the U.S.'s most productive oil regions, along with assets in the Rockies, Latin America, and the Middle East. Its business model emphasizes efficient drilling, low-cost production, and carbon capture initiatives aimed at long-term sustainability.
The ProShares UltraShort Bloomberg Natural Gas (KOLD) is a leveraged inverse exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to two times the inverse (-2x) of the daily performance of the Bloomberg Natural Gas Subindex. This subindex reflects the natural gas segment of the commodities market by tracking futures contracts, primarily the second-month Henry Hub natural gas futures, weighted by liquidity and production. The fund does not invest directly in physical natural gas but uses derivatives like futures contracts and swaps to achieve its objective.
Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.